Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
Open Access
- 6 September 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 115 (7), 789-796
- https://doi.org/10.1038/bjc.2016.271
Abstract
Background: : Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, first-line, proof of concept study (NCT01303172), explored safety and tolerability of IMM-101 (heat-killed Mycobacterium obuense; NCTC 13365) with gemcitabine (GEM) in advanced pancreatic ductal adenocarcinoma. Methods: : Patients were randomised (2 : 1) to IMM-101 (10 mg ml−l intradermally)+GEM (1000 mg m−2 intravenously; n=75), or GEM alone (n=35). Safety was assessed on frequency and incidence of adverse events (AEs). Overall survival (OS), progression-free survival (PFS) and overall response rate (ORR) were collected. Results: : IMM-101 was well tolerated with a similar rate of AE and serious adverse event reporting in both groups after allowance for exposure. Median OS in the intent-to-treat population was 6.7 months for IMM-101+GEM v 5.6 months for GEM; while not significant, the hazard ratio (HR) numerically favoured IMM-101+GEM (HR, 0.68 (95% CI, 0.44–1.04, P=0.074). In a pre-defined metastatic subgroup (84%), OS was significantly improved from 4.4 to 7.0 months in favour of IMM-101+GEM (HR, 0.54, 95% CI 0.33–0.87, P=0.01). Conclusions: : IMM-101 with GEM was as safe and well tolerated as GEM alone, and there was a suggestion of a beneficial effect on survival in patients with metastatic disease. This warrants further evaluation in an adequately powered confirmatory study.Keywords
This publication has 22 references indexed in Scilit:
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- The immune network in pancreatic cancer development and progressionOncogene, 2013
- Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapyZeitschrift für Krebsforschung und Klinische Onkologie, 2013
- Immunotherapy updates in pancreatic cancer: are we there yet?Therapeutic Advances in Medical Oncology, 2012
- Pancreatic adenocarcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2012
- Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapyCancer Immunology, Immunotherapy, 2011
- An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanomaAnnals of Oncology, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 StudyJournal of Clinical Oncology, 2010
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2009